So, BLKBRD Asset Management dumped all their Hims & Hers stock. All of it. $18.07 million worth. You know, the telehealth thing? The one where you get… stuff… delivered? Honestly, it’s just… a choice. A choice they made. And now they’re out. And people are acting like this is some grand revelation. It’s a stock. They sold a stock. What is happening with people?
What Happened, Exactly?
Apparently, back in February – February! – BLKBRD decided Hims & Hers wasn’t for them anymore. They offloaded 318,666 shares. 318,666! Who even counts that high? It’s just… excessive. And now we’re all supposed to care because it moved the market? It’s like they’re intentionally trying to manufacture drama. The transaction value? $18.07 million. Again with the sevens! It’s always the sevens. Net change? Also $18.07 million. They just… really wanted to emphasize the $18.07 million. It’s… unsettling.
More Information. Because We Need More Information.
- They completely exited the position. Gone. Zero. Used to be 5% of their holdings. Five percent! That’s a significant chunk of… whatever it is they’re managing. Now it’s just… nothing.
- As of December 31st, their top holdings? NVDA – $4.66 million. GOOGL – $4.28 million. Predictable. It’s always the same. Everyone piles into the same things. Where’s the originality?
- Hims & Hers stock is down 72.46% over the past year. 72.46%! It’s practically giving money away. And they’re comparing it to the S&P 500? As if that makes it better. It’s all relative, I guess. But still.
The Company, Briefly. Because We Have To.
| Metric | Value |
|---|---|
| Price (Feb 13, 2026) | $16.30 |
| Market cap | $3.57 billion |
| Revenue (TTM) | $2.21 billion |
| Net income (TTM) | $133.79 million |
What They Do. If You Must Know.
- They offer telehealth. You talk to a doctor on your computer. Groundbreaking.
- They sell… things. Wellness products, skincare, hair care. The usual.
- They target “health-conscious consumers.” Which is just a fancy way of saying people who are easily marketed to.
Hims & Hers is a multi-specialty telehealth platform. They integrate digital healthcare with wellness products. It’s a whole… ecosystem. And it’s all based on subscriptions. Subscriptions! Like we don’t have enough things to remember to cancel. They combine medical consultations, prescription fulfillment, and branded wellness products. It’s all very… seamless. Too seamless, if you ask me. It feels… calculated.
What Does This Mean for Investors?
Hims & Hers stock has been in a freefall since last June. Last June! When it was trading near $64. Now it’s around $15. It’s like watching a slow-motion disaster. The problem? Novo Nordisk terminated their partnership to sell weight-loss drugs. And then sued them. For selling copycat drugs. Can you believe the audacity? And Hims & Hers was one of the most shorted midcap stocks. Of course it was. It’s practically begging to be shorted.
But then, on Tuesday, March 10th, everything changed. They announced a new partnership with Novo Nordisk. To offer Ozempic and Wegovy. And Novo Nordisk dropped the lawsuit. Suddenly, the stock is up 6%. Six percent! It’s like they’re making it up as they go along. The stock is still trading at a high multiple. But this news might give investors a reason to… reassess. Or it might just be another temporary bump before it goes back down. Honestly, who can tell anymore? It’s all just… noise.
Read More
- Building 3D Worlds from Words: Is Reinforcement Learning the Key?
- Gold Rate Forecast
- Securing the Agent Ecosystem: Detecting Malicious Workflow Patterns
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- The Best Directors of 2025
- Mel Gibson, 69, and Rosalind Ross, 35, Call It Quits After Nearly a Decade: “It’s Sad To End This Chapter in our Lives”
- TV Shows Where Asian Representation Felt Like Stereotype Checklists
- Games That Faced Bans in Countries Over Political Themes
- 📢 New Prestige Skin – Hedonist Liberta
- Most Famous Richards in the World
2026-03-10 23:12